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IntroductIon
Type-2 immune responses are thought to have evolved as 
protective mechanisms against parasitic infections, especially 
against helminths. More recently, they have also been associ-
ated with wound repair and reestablishing tissue homeosta-
sis (Wynn, 2015). Because of increased hygiene and possibly 
other factors, diseases characterized by aberrant forms of 
type-2 immunity, including allergies, have become a major 
health burden in western societies. Asthma is a prime exam-
ple of a widespread, chronic inflammatory disease affecting 
300 million people worldwide. This disease of the respiratory 
tract is classically associated with reversible airway obstruc-
tion, airway hyperresponsiveness, infiltration of eosinophils, 
mucus production, and a Th2-type inflammation (Gregory 
and Lloyd, 2011). It is generally induced by allergens, such as 
house dust-mite fecal pellets (von Mutius, 2009). Allergens 
are inhaled and, upon reaching the airways, are recognized by 
epithelial cells through pattern-recognition receptors, leading 
to the secretion of inflammatory mediators, such as thymic 
stromal lymphopoietin and IL-33, which, in turn, activate 
group 2 innate lymphocytes (ILC2s) and DCs to initiate al-
lergen-specific immune responses (Willart et al., 2012). DCs, 
as specialized APCs, are essential for the uptake, transport, 
and subsequent presentation of these innocuous antigens to 
T cells (van Rijt et al., 2005), which are the main drivers of 
allergy-associated inflammation in the lung once individuals 
are reexposed to the allergen (Kopf et al., 1993).
Peroxisome proliferator-activated receptor γ (PPARγ) 
is a lipid-activated transcription factor that has an import-
ant role in regulating genes associated with lipid metab-
olism as well as being essential for adipocyte development. 
In the immune system, PPARγ is thought to have an im-
portant role in polarization of macrophages toward an M2 
or anti-inflammatory phenotypes (Bouhlel et al., 2007), and 
PPARγ, acting in CD4+ T cells, has been suggested to in-
hibit Th17 differentiation and thereby suppress autoimmu-
nity in the central nervous system (Klotz et al., 2009). More 
recently, our laboratory showed that PPARγ is essential for 
the development of alveolar macrophages (AMs) in the lung 
and that, in its absence, animals develop pulmonary alveolar 
proteinosis (Schneider et al., 2014b). In the context of pul-
monary, allergic inflammation, it has been shown that treat-
ment with PPARγ agonists, such as rosiglitazone, dampens 
inflammation, and that has been linked to an inhibitory role 
in DCs and eosinophils (Woerly et al., 2003; Hammad et al., 
2004). However, the underlying mechanism, and which cell 
types are actually targeted by these agents, is largely unclear. 
To more thoroughly address the role of PPARγ in type-2 
immunity, we studied the cell-intrinsic role of PPARγ in two 
key immune cell types in this context, i.e., antigen-presenting 
DCs as initiators and Th2 cells as drivers of type-2 responses.
We find that PPARγ, in both T cells and DCs, controls 
development of type-2 immunity. In CD4+ T cells, PPARγ is 
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highly expressed in both mouse and human Th2 cells and in-
trinsically controls Th2 differentiation and effector function. 
In addition, in lung CD11b+ DCs, PPARγ intrinsically con-
trols priming of naive T cells toward Th2 polarization in vivo. 
Thus, we uncover a surprising and, thus far, unappreciated, 
proinflammatory role of PPARγ in type-2 immunity.
resuLts
PPArγ intrinsically controls th2 effector function in vivo
We aimed to address the role of PPARγ comprehensively in 
the context of allergic inflammation and decided to focus first 
on T cells as key drivers (i.e., Th2 cells) and regulators (i.e., 
regulatory T cells [Treg cells]) of type-2 immune responses. 
For this purpose, we generated T cell–specific PPARγ KO 
animals by crossing Ppargfl/fl to mice expressing Cre under 
the Cd4 promoter. To assess the specificity and efficiency 
of CD4–Cre-mediated deletion, we crossed Cd4–Cre an-
imals to the Rosa26-RFP-Cre reporter strain (Cd4-Cre 
Rosa26f/l+ RFP) and evaluated RFP expression in different 
cell types. 85–90% of CD4+ and CD8+ T cells were found to 
be RFP+, whereas other cell types were barely affected, with 
the exception of ILCs, where 10% of cells were found to 
express RFP (Fig. S1 A).
To evaluate the T cell intrinsic role of PPARγ in pul-
monary allergic immunity, we sensitized Ppargfl/fl Cd4–Cre 
and Cre-negative controls with house dust mite extract 
(HDM) as a common model for type-2 allergic inflamma-
tion. To evaluate the impact of T cell–specific deletion of 
PPARγ on the development of asthmatic inflammation, we 
quantified pulmonary eosinophilia, one of the classical hall-
marks of this disease, in animals subsequently challenged with 
PBS or HDM, as indicated in the scheme (Fig. S1 B). HDM 
challenge induced significant recruitment of eosinophils into 
the bronchoalveolar lavage (BAL) and lungs of control an-
imals (Fig.  1  A). However, the number of eosinophils was 
strongly reduced in Ppargfl/fl Cd4–Cre mice, whereas the 
number of neutrophils was unchanged (Fig. 1 A). In addition, 
peribronchial inflammation, as well as the number of mucus 
cells, was strongly reduced in T cell–specific, PPARγ KO an-
imals (Fig. 1 B), and a trend toward lower levels of IgE could 
be observed (Fig. S1 C). Furthermore, the number of CD4+ 
T cells was slightly reduced in the in the BAL of Ppargfl/fl 
Cd4–Cre animals (Fig.  1 C). To evaluate whether intrinsic 
deletion of PPARγ in CD4+ T cells might directly affect 
polarization and the T cell effector response, we measured 
their cytokine profile (i.e., Th1, Th2, Th17) and ST2 expres-
sion. The frequency of IL-4–, IL-5–, and IL-13–expressing 
cells was strikingly reduced, whereas IFN-γ– or IL-17– 
expressing cells were enhanced or unchanged, respectively, in 
Ppargfl/fl Cd4–Cre mice in the BAL (Fig.  1 D). Consistent 
with a reduction of Th2 cytokine-producing cells, the fre-
quency of CD4+ T cells expressing ST2 (IL-33R), a surface 
marker of Th2 cells (Lambrecht et al., 2000) was reduced in 
the absence of PPARγ (Fig. 1 E), whereas pulmonary ILC2 
cells remained unaffected (Fig. 1 F). Characterizing the Treg 
compartment of HDM-treated animals, we found that the 
number of Treg cells was significantly reduced in the lung, 
but not in lung-draining LNs, of Ppargfl/fl Cd4–Cre mice 
compared with controls (Fig. 1 G). Treg cells were recently 
described to consist of distinct subsets that can be distin-
guished by expression of the transcription factors RORγt 
and GATA3 (Wohlfert et al., 2011; Ohnmacht et al., 2015). 
We, therefore, examined the impact of T cell–specific dele-
tion of PPARγ on the makeup of the Treg compartment. 
Indeed, we found that the frequency of GATA3-expressing 
CD4+FoxP3+ cells was reduced, whereas Treg cells expressing 
RORγt were unaffected by the loss of PPARγ (Fig.  1 H). 
Corroborating a role of PPARγ in Th2 and Treg develop-
ment, we found that Pparg expression was highly expressed in 
pulmonary ST2+CD4+ T cells and, to a lesser extent, in Treg 
cells (i.e., Foxp3-GFP+CD4+ T cells isolated from DER EG 
mice) compared with ST2−CD4+ (non-Th2) cells at the peak 
of HDM-induced lung inflammation (Fig. 1 I).
To evaluate whether that deficiency in T cell–driven, 
type-2 immunity was specific to the HDM model, we tested 
Ppargfl/fl Cd4–Cre animals in the widely used OVA/Alum 
experimental asthma model (Fig. S1 D). Very similar to the 
HDM model, the number of eosinophils in the BAL was 
strongly reduced, whereas the number of neutrophils was 
somewhat increased (Fig. S1 E). Again, a trend toward fewer 
CD4+ T cells infiltrating in the BAL could be observed in 
the BAL of T cell–specific PPARγ KO animals (Fig. S1 F). 
Moreover, IL-4+ and IL-5+ CD4+ T cells, but not IFN-γ+ and 
IL-17+ CD4+ T cells, were significantly impaired if they in-
trinsically lacked PPARγ (Fig. S1 G). Collectively, these results 
suggest that PPARγ critically and specifically regulates Th2 
effector function in vivo in different settings as well as having 
a minor role in regulating the phenotype of lung Treg cells.
PPArγ in t cells intrinsically controls th2 effector program
Having observed a profound deficiency in Th2 effector func-
tion in vivo, we wanted to more thoroughly address the un-
derlying mechanism using an in vitro co-culture system. When 
naive CD4+ T cells were polarized into Th1, Th2, and Th17 
subsets in vitro and PPARγ expression was evaluated, it be-
came evident that expression of PPARγ mRNA and protein 
was highest in Th2 cells (Fig. 2, A and B), almost reaching ex-
pression levels of AMs (Fig. 2 C). Furthermore, under neutral 
conditions (i.e., peptide stimulation alone), T helper cell cy-
tokine production was significantly changed in the absence of 
PPARγ. The frequency of cells expressing IL-4, and in partic-
ular IL-5, was strongly reduced (Fig. 2 D), Conversely, IFN-γ 
producers were comparable, and IL-17A producers were even 
enhanced in the absence of PPARγ (Fig.  2  D). To address 
whether PPARγ was required for differentiation of Th2 cells 
or for maintenance of effector function, naive Smarta-1 trans-
genic CD4+ T cells were co-cultured with splenic DCs and 
peptides in the presence of the PPARγ-antagonist GW9662. 
The antagonist was added either from the beginning or after 4 
d of culturing. Examining the frequencies of ST2+, IL-4+, and 
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Figure 1. PPArγ in t cells mediates development of pulmonary allergic inflammation. (A–I) Ppargfl/fl and Cd4-CrePpargfl/fl mice were sensitized intra-
tracheally with 10 µg HDM on d 0 and subsequently challenged intratracheally with 10 µg HDM or PBS on days 7–11. Animals were analyzed on day 14. Flow 
cytometry was used to characterize and quantitate BAL and lung cell populations, including eosinophils (A) and neutrophils (B). (B, top) Hematoxylin and 
eosin histology. (B, bottom) PAS and Alcian blue histology. CD4+ and CD8+ T cells (C) and BAL CD4+ T cells (D) were restimulated with PMA/ionomycin for 4 h. 
Shown is the frequency of CD4+ T cells that produced the indicated cytokines. The data presented are pooled from two independent experiments (n = 5–11/
group). Shown are ST2+CD4+ Th2 cells (E), lin−CD90+CD127+CD25+ ILC2s (F), Foxp3+CD4+ Treg cells (G), and GATA3+ and RORγt+ cells (H) among CD4+FoxP3+ 
Treg (n = 4–6/group). (I) DER EG mice were treated with HDM as described in this legend. GFP+CD4+ Treg, ST2+CD4+ Th2, and ST2−CD4+ non-Th2 cells were 
sorted on day 14 by flow cytometry. Shown is the Pparg mRNA expression measured by quantitative PCR (n = 3/group). The data are representative of three 
experiments. Data are means ± SEM and the sample size (n). The Student’s t test (unpaired) was used. *, P < 0.05; **, P < 0.01.
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IL-5+ cells, it became evident that PPARγ blockade during 
the entire differentiation period strikingly affected genera-
tion of ST2+ and IL-5+ cells in a dose-dependent manner, 
whereas IL-4+ cells were moderately reduced (Fig. 2 E). In 
contrast, IFN-γ remained unaffected and, paradoxically, IL-17 
production was increased or decreased dependent on the 
amount of inhibitor (Fig. 2 E). Furthermore, PPARγ block-
ade in already-differentiated cells inhibited ST2, IL-4, and 
IL-5 production, although not as pronounced as with block-
ade throughout the entire co-culture period. Conversely, no 
effect was seen on IL-17A and IFN-γ production (Fig. S1, H 
and I). In conclusion, these results suggested that PPARγ pro-
motes Th2 differentiation and effector function, in particular, 
for expression of IL-5 and ST2.
PPArγ is dispensable for treg function in vitro
Because we had observed a difference in the phenotype of 
Treg cells intrinsically lacking PPARγ in pulmonary mod-
els of type-2 immunity, we wanted to explore the possibil-
ity that PPARγ directly regulated Treg function. For that 
purpose, we conducted Treg suppression assays with naive 
CD4+CD25− T cells from WT and Treg cells isolated from 
Ppargfl/fl Cd4–Cre or Ppargfl/fl mice. PPARγ-deficient Treg 
cells, sorted from HDM-inflamed lungs (Fig. S1, J and K) 
or naive spleens (not depicted), suppressed proliferation and 
cytokine production comparably in this setting. Overall, these 
results suggest that the main functions of Treg cells were intact 
in the absence of PPARγ.
PPArγ suppresses a th17/th22 transcriptional 
program and is essential for IL-33–induced cd4+ t cell 
effector cytokine production
To better characterize the role of PPARγ in controlling Th2 
effector function, we performed RNA sequencing of T cells 
co-cultured with DCs and PPARγ antagonist or vehicle, 
similar to the setup described in Fig. 2. Examining the most 
differentially regulated genes confirmed a strong reduction 
in expression of Il5 and Il1rl1 (IL-33 receptor; ST2) RNA 
(Fig. 3, A and B). In addition, multiple genes associated with 
Th17 effector function were significantly increased in expres-
sion, including Il17f, Il22, and Rorc. No significant differ-
ences could be detected in Il4 and Il13 RNA levels (Fig. 3 B). 
To confirm enhanced expression of Th17-associated cyto-
kines IL-17F and IL-22, Smarta-1 splenic CD4+ T cells were 
co-cultured with DCs in the presence of polarizing cytokines. 
The frequency of both IL-17F– and IL-22–expressing CD4+ 
T cells was significantly higher in PPARγ antagonist-treated 
cells, in particular, under Th22-polarizing conditions (Fig. 3, 
C and D). Having established that PPARγ predominantly 
promotes IL-5 and ST2 expression in vitro, we hypothesized 
that the general impairment of Th2 immunity observed in 
vivo is mainly due to the lack of PPARγ-deficient Th2 cells 
to respond to IL-33 produced by lung epithelia but are ab-
sent in our in vitro culture protocol. To test that hypothe-
sis, we co-cultured Smarta-1 splenic CD4+ T cells with WT 
or Il1rl1−/− splenic DCs in the presence of IL-4 and IL-33 
and PPARγ antagonist. IL-4, alone, potently induced ST2 
cell surface expression on CD4+ T cells and IL-5 produc-
tion, and that was further enhanced when IL-33 was added 
to the culture (Fig.  3  E). Because IL-33 alone had no ef-
fect, IL-4 together with IL-33 seems to act in synergy. This 
significant increase in both ST2 and IL-5 was indepen-
dent of ST2 (IL-33R) expression on splenic DCs because 
co-cultures using Il1rl1−/− splenic DCs revealed the same re-
sults (Fig. 3 F). Overall, these results suggested that PPARγ 
both suppressed a Th17-associated effector program and pro-
moted Th2 responsiveness to IL-33, which in vivo strongly 
promotes Th2 effector function.
PPArγ is highly expressed and strongly associated with 
crth2+ type-2 human memory t cells
Having established an essential role of PPARγ in controlling 
Th2 effector function in mice, we wanted to investigate 
whether this transcription factor could also be used as a 
marker and potential therapeutic target in human-memory 
Th2 cells. For that purpose, T cell clones were generated from 
allergic and non-allergic donors by sorting different T helper 
cell subsets according to differential chemokine receptor ex-
pression and subsequent culture in vitro. That lead to very 
distinct cytokine expression profiles of individual clones, as re-
cently described (Becattini et al., 2015). T cell clones from the 
CXCR3+CCR4−CCR6− subset (enriched in Th1 cells) were 
characterized by expressing high levels of IFN-γ, whereas T 
cells clones from the CXCR3+CCR4−CCR6+ subset (en-
riched in Th1*) in addition also expressed significant levels of 
IL-17A (Fig. 4, A and B). Conversely, T cell clones from the 
CRTh2+CCR4+ and, to a lesser extent, CRTh2−CCR4+ sub-
set (enriched in Th2) expressed high levels of IL-4 and IL-5 
(Fig. 4, A and B). Clones from the CXCR3−CCR4+CCR6+ 
subset (enriched in Th17), in contrast, almost exclusively ex-
pressed IL-17A (Fig. 4, A and B). Having validated the dis-
tinct cytokine expression patterns, we determined PPA RG 
expression levels in all of these different clones under differ-
ent stimulation conditions. Strikingly, after stimulation with 
PMA/ionomycin, both PPA RG transcripts were expressed 
by far the highest in CRTh2+CCR4+ cells derived from al-
lergic donors (Fig. 4, C and D), as opposed to all other types 
of clones. Similarly, stimulation with αCD3 also revealed a 
specific expression of PPA RG in CRTh2+CCR4+ clones 
(Fig. S2, A and B). HDM-reactive CRTh2+CCR4+ Th2 cells 
from an HDM-allergic donor also expressed higher PPARγ 
mRNA compared with HDM-reactive CCR4− non-Th2 
cells (not depicted). In clones derived from non-allergic do-
nors, a similar expression pattern could be observed, although 
PPA RG expression levels were generally lower than in cells 
derived from IgE− individuals (Fig. 4, E and F). To corrob-
orate these results, memory CD4+ T cells were isolated di-
rectly ex vivo from multiple allergic and non-allergic donors, 
and PPA RG expression was quantified. Similar to the pattern 
observed in the donor-derived clones, the highest express-
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Figure 2. PPArγ is highly expressed in mouse t cells and controls th2 polarization in vitro. Naive splenic CD4+ T cells were sorted from Ppargfl/fl 
and Cd4-CrePpargfl/fl mice and were co-cultured for 4 d with splenic DCs and soluble αCD3 mAbs (2 µg/ml). Shown are the Pparg mRNA of Ppargfl/fl cells 
(WT; A) and the intracellular protein expression of PPARγ in Ppargfl/fl cells (B), with the corresponding Cd4-CrePpargfl/fl controls and PPARγ expression in 
AMs as a comparison (C). (D) Cytokine production profile after 4 h restimulation with PMA/ionomycin (n = 4/condition). (E and F) naive, splenic, Smarta-1, 
transgenic CD4+ T cells were co-cultured with splenic DCs and 10 nM gp61 peptide in polarizing conditions in the presence of PPARγ antagonist GW9662 
at the indicated concentrations or in vehicle (DMSO) as a control. Shown are the frequencies of ST2+ and cytokine-producing cells of indicated cytokines 
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ing samples were found in the CRTh2+CCR4+ subset, al-
though no differences could be observed between IgE+ and 
IgE− individuals (Fig. 4, G and H). We hypothesized that the 
lack of difference between allergic and non-allergic donors 
in the ex vivo samples could reflect the need for PPA RG to 
be induced by an activating stimulus. To address that ques-
tion, selected CRTh2+ Th2 and Th1 clones were stimulated 
with αCD3 for different times, and PPA RG expression was 
measured. Indeed PPA RG expression was strongly induced 
after activation in CRTh2+ Th2 clones but not in Th1 cells 
(Fig. S2, E and F). Collectively, these results suggested that 
PPARγ is a specific marker for allergic CRTh2+ Th2 cells in 
humans and that its expression in human T cells is dependent 
on an activating stimulus.
PPArγ in cd11c+ cells controls th2 immunity in vivo
After having established a critical role for PPARγ in the 
regulation of Th2 immunity in T cells in vivo and having 
discovered that PPARγ regulates Th2 responsiveness to tis-
sue-derived signaling molecule IL-33, we sought to further 
characterize the role of this transcription factor in other cells, 
which have an important role in allergic inflammation. In-
deed, we were particularly interested in cells that are known 
to interact closely with T cells and the lung epithelium. We 
decided to focus on the mononuclear phagocyte compart-
ment of the lung, which is essential for induction and regu-
lation of pulmonary immunity (Kopf et al., 2015) and which 
has been shown to respond strongly to tissue-derived signals, 
including IL-33 (Kurowska-Stolarska et al., 2009; de Kleer et 
al., 2016). In the lung, this compartment is mainly composed 
of DCs and AMs, and both of those cell types express CD11c 
(Schneider et al., 2014b; Nobs et al., 2015). We, therefore, 
crossed our Ppargfl/fl animals to mice expressing Cre under 
the CD11c promoter (Ppargfl/fl Itgax–Cre) to specifically tar-
get these cells. To check specificity and efficacy of Itgax-Cre 
activity, we generated Itgax-Cre, Rosa26 flstopfl-RFP reporter 
mice. Both in naive (Fig. S3 A) and inflamed lungs (Fig. S3, 
B and C), conventional DC subsets and monocyte-derived 
DCs, as well as AMs, were efficiently targeted by CD11c-Cre– 
mediated deletion. To avoid misinterpretation of the results 
from potential targeting of other cells, key cell types in pulmo-
nary allergic inflammation were also evaluated for their RFP 
expression. Indeed, only very few eosinophils, neutrophils, 
and epithelial cells exhibited CD11c-Cre activity (Fig. S3, B 
and C). We initially characterized Ppargfl/fl Itgax-Cre mice in 
the naive state. These animals have immature AMs (Fig. S3, 
D and E) because of the requirement of PPARγ in AM fetal 
development, as recently described (Schneider et al., 2014b). 
This developmentally arrested population expresses higher 
levels of CD11b, is more autofluorescent (Fig. S3 F), and is 
largely nonfunctional, leading to the development of pulmo-
nary alveolar proteinosis in Ppargfl/fl Itgax-Cre mice (Schnei-
der et al., 2014b). The DC compartment in these animals, in 
contrast, develops normally (Fig. S3, G and H). To study the 
role of PPARγ in CD11c+ mononuclear phagocytes, Ppargfl/fl 
Itgax-Cre animals were tested in an HDM model of pul-
monary allergic inflammation (Fig. 5 A). Interestingly, infil-
tration of eosinophils was strongly reduced in the absence 
of PPARγ in CD11c+ cells (Fig.  5  B). Although the total 
number of CD4+ and CD8+ T cells was unaffected (Fig. 5 C), 
the level of BAL IgE was significantly reduced in Ppargfl/fl 
Itgax-Cre mice (Fig. 5 D). To test whether these surprising 
findings were specific to HDM as the allergen, we subjected 
CD11c-specific PPARγ KO mice to the classical OVA/Alum 
model (Fig. 5 E). The results observed using OVA, instead of 
HDM, were very similar because, again, a significant reduc-
tion in pulmonary eosinophilia could be observed (Fig. 5 F). 
In addition, a moderate decrease in the number of CD4+ T 
cells was also visible in this model (Fig. 5 G). Overall, these 
results indicated that PPARγ in a CD11c-expressing cell 
type is required for induction of asthmatic inflammation. 
This result immediately raised the question as to the identity 
of this cell type. Because it was already clear that AMs were 
nonfunctional in the absence of PPARγ, from earlier studies 
(Schneider et al., 2014b), we wanted to elucidate the gen-
eral function of these cells in our setting. For this purpose, 
AMs were depleted with clodronate before subsequent sen-
sitization and challenge with HDM (Fig. 5 H). Clodronate 
specifically eliminates AMs (Fig. S4 A), whereas lung-resident 
DCs are not affected (Fig. S4, B–D). AM depletion before 
HDM treatment resulted in a much more-pronounced in-
flammation, with increased infiltration of eosinophils and 
neutrophils (Fig.  5  I). Moreover, the total number of lung 
CD8+ and CD4+ T cells (Fig. 5 J) were also increased in the 
absence of AMs, whereas the T helper cell subset differen-
tiation at the single-cell level was not significantly affected 
(Fig. 5 K). These data confirm previous studies showing that 
AMs interfere with T cell activation and, therefore, suppress 
lung inflammation (Thepen et al., 1989; Holt et al., 1993; 
Soroosh et al., 2013). Because AM depletion and PPARγ de-
ficiency in AMs and DCs had the opposite effects on type-2 
inflammation, we hypothesized that PPARγ deficiency in 
DCs, rather than AMs, was responsible for impaired type-2 
inflammation in the lung.
PPArγ in dcs controls type-2 immunity in vivo
To address the role of PPARγ specifically in pulmonary DCs, 
neonatal Ppargfl/fl Itgax-Cre animals (CD45.2) were treated 
intratracheally with CD45.1+ cells harvested from the lungs 
of WT E17.5 embryos, which contain immediate AM precur-
after restimulation with PMA/ionomycin. (E) GW9662 was added from the beginning and cells were analyzed after 4 d of culture (n = 4/condition). (F) Cells 
were cultured for 4 d before addition of GW9662 and analyzed 24 h later (n = 4/condition). The data are representative of three independent experiments. 
Data are means ± SEM and the sample size (n). ANO VA (one-way) was used. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.
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Figure 3. PPArγ suppresses a th17/th22 transcriptional program and is essential for IL-33–induced cd4+ t cell effector cytokine production. 
Naive splenic Smarta-1 transgenic CD4+ T cells were co-cultured with splenic DCs and 10 nM gp33 peptide in Th2 polarizing conditions in the presence 
of PPARγ antagonist GW9662 or vehicle (DMSO) as a control. After 4 d of co-culture, RNA sequencing of CD4+ T cells was performed (n = 2). Heat map 
of the 100 most-differentially regulated genes (A) and expression levels of selected Th2 cytokines (B). (C) Naive splenic Smarta-1 transgenic CD4+ T cells 
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sors (Fig. 6 A). 8 wk later, AM-reconstituted, adult Ppargfl/fl 
Itgax-Cre mice were then subjected to HDM-induced ex-
perimental asthma. Lung analysis of Ppargfl/fl Itgax-Cre re-
vealed that mice were completely reconstituted with WT 
AMs (Fig. S4 E) because the WT precursors outcompeted 
the PPARγ KO cells (Schneider et al., 2014b), leading to 
a functional AM compartment (Schneider et al., 2014a). 
HDM immunization and subsequent challenge with HDM 
or PBS revealed that HDM-treated animals, which lacked 
PPARγ only in DCs, exhibited a pronounced reduction in 
pulmonary eosinophilia in both BAL (Fig.  6  B) and lung 
(Fig.  6  C), similar to the phenotype observed in Ppargfl/fl 
Itgax-Cre mice, which had not been reconstituted (Fig. 5 B). 
Furthermore, histological analysis showed that they had 
a lower frequency of mucus-producing cells and reduced 
areas of peribronchial lymphoid follicles (Fig.  6 D). In ad-
dition, a trend toward fewer CD4+ T cells in the BAL was 
also observed (Fig. 6 E). Because DCs are potent inducers of 
T cell–mediated immunity, we carefully analyzed the CD4+ 
T cell response in AM-reconstituted Ppargfl/fl Itgax-Cre an-
imals. The frequency of IL-4+, IL-5+, and IL-13+ cells was 
significantly reduced in animals lacking PPARγ specifically 
in DCs (Fig. 6 F). No significant differences could be seen 
in the number of ILC2s (Fig. 6 G). To corroborate those re-
sults, DC-specific PPARγ KO animals were also tested in the 
OVA/Alum experimental asthma model. Similar to the re-
sults obtained with HDM-induced allergic inflammation, the 
number of eosinophils in the lung was significantly reduced 
in AM-reconstituted Ppargfl/fl Itgax-Cre mice (Fig.  6  H). 
Although no differences could be observed in the number 
of CD4+ or CD8+ T cells (Fig.  6  I), the frequency of IL-
4+CD4+ T cells (Fig. 6 J) as well as the amount of IL-4 (mean 
fluorescence intensity [MFI]) produced at the single-cell 
level was significantly reduced if the lung DC compartment 
was devoid of PPARγ (Fig. 6 J), whereas the frequencies of 
IFN-γ– and IL-17A–producing cells were not different from 
Ppargfl/fl controls (Fig. 6 J), Overall, these results indicated that 
PPARγ intrinsically in lung-resident DCs promotes induc-
tion of Th2 immunity in vivo.
PPArγ is dispensable for antigen uptake but 
modulates migration of lung cd11b+ dcs to the 
lung draining Lns (dLns)
Having established that PPARγ in lung DCs mediates induc-
tion of type-2 immunity, we wanted to further elucidate the 
underlying mechanisms. One of the central aspects of DC 
biology is the capacity to take up antigen and transport it to 
the dLNs to enable priming of naive T cells. To assess a poten-
tial role for PPARγ in this process, we administered AF-488 
labeled OVA (OVA-AF488) with HDM to AM-reconstituted 
Ppargfl/fl Itgax-Cre mice and evaluated the uptake and trans-
port of OVA by lung DCs. Although the frequency of OVA+ 
cells among CD103+ and CD11b+DCs in the lung dLN was 
similar between DC-specific PPARγ KO animals and con-
trols (Fig. 7 A), the total number of OVA-carrying CD11b+ 
DCs was significantly reduced in AM-reconstituted Ppargfl/fl 
Itgax-Cre mice (Fig. 7 B). In the lung, no differences could 
be observed in the frequency of OVA+ cells within each 
DC subset (Fig. 7 C) or in the total number of OVA+ DCs 
(Fig. 7 D). To elucidate whether DC activation was somehow 
impaired in the absence of PPARγ, we analyzed the surface 
expression of a variety of activation markers on DCs in the 
lung dLN as well as the lung. No significant differences in 
CD80, CD86, or CD40 could be observed in migratory LN 
DCs or lung-resident DCs (Fig. 7 J). Similarly, no difference 
could be observed in the expression of the IL-33 recep-
tor ST2 between WT and PPARγ-deficient cells for dLNs 
(Fig. 7 K) and lung (Fig. 7 L). Overall, these results suggested 
that PPARγ is dispensable for antigen uptake and activation 
of lung DCs but allows better migration of antigen-loaded 
lung CD11b+ DCs to the lung dLN.
PPArγ intrinsically modulates th2 
polarization capacity in lung dcs
To address a direct DC-intrinsic role of PPARγ in priming 
naive CD4+ T cells, we sorted naive migratory lung DCs from 
AM-reconstituted Ppargfl/fl Itgax-Cre mice and co-cultured 
them with OTII-transgenic, naive CD4+ T cells in vitro. Eval-
uating the CD4+ T cell cytokine production profile revealed 
that the frequency of IL-4–producing cells was significantly 
reduced if DCs lacked PPARγ in both CD103+ and CD11b+ 
conventional DC subsets analyzed (Fig.  8  A). In contrast, 
Th1 and Th17 polarization was unaffected in cultures con-
taining PPARγ-deficient CD11b+ DCs and was slightly re-
duced in cultures containing PPARγ-deficient CD103+ DCs 
(Fig. 8 A). Induction of CD4+ T cell proliferation appeared 
to be also completely intact, despite the DC-intrinsic defi-
ciency of PPARγ (Fig. 8 B). Having established a modulating 
role of PPARγ for lung DC-induced Th2 differentiation in 
vitro and CD11b+ DC-mediated antigen transport, we aimed 
to elucidate the importance of PPARγ for each of the two 
major lung DC subsets, CD103+ and CD11b+ DCs, in an 
in vivo setting. For that purpose, Ppargfl/fl Itgax-Cre mice 
reconstituted with WT AMs were injected with HDM, and 
were co-cultured with splenic DCs and 10 nM gp61 peptide in Th2 or Th22 polarizing conditions in the presence of PPARγ antagonist GW9662 or vehicle 
(DMSO) as a control. (C and D) Shown is the production of IL-17F (C) and IL-22 (D) after 4-h restimulation with PMA/ionomycin (n = 4/condition). (E and F) 
Naive splenic Smarta-1 transgenic CD4+ T cells were co-cultured with splenic DCs purified from WT or Il1rl1−/− mice and 1 nM gp61 peptide with indicated 
cytokines and in the presence of PPARγ antagonist GW9662 or vehicle (DMSO) as a control. Frequencies of IL-5+ (E) and ST2+ (F) of CD4+ cells after 4 h 
restimulation with PMA/ionomycin (n = 4/condition) for co-culture with) WT (E and Il1rl1−/− (F) splenic DCs (n = 4/condition). Data are means ± SEM and 
are representative of two independent experiments. The Student’s t test (unpaired) was used. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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Figure 4. PPArγ is highly expressed in human effector memory th2 cells. Effector memory T cells were sorted from PBMCs of human allergic 
and non-allergic donors, according to chemokine receptor expression and subsequently cultured in vitro as described in the Materials and methods sec-
tion. T cells were pregated as CD4+CD8–CD14–CD19–CD25–CD56–CD45RA– CCR7– cells, and subsequently, T cell subsets were identified as follows: CRTh2+ 
CCR4+CXCR3–CCR6– (enriched in inflammatory Th2 cells); CCR4+CRTh2–CXCR3–CCR6– (enriched in Th2 cells); CXCR3+CCR4–CCR6– (enriched in Th1 cells); 
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lung DCs were sorted and transferred to naive WT recipients 
after 24 h. These animals were then subsequently challenged 
with HDM and the type-2 immune response was evaluated. 
Strikingly, transfer of either WT or Pparg-deficient CD103+ 
DCs poorly induced eosinophil and neutrophil recruitment 
(Fig.  8  C). In contrast, transfer of HDM-pulsed CD11b+ 
DCs resulted in a potent eosinophilia and weak neutro-
philia in the lung (Fig. 8 C), which was strongly dependent 
on the presence of PPARγ in the transferred DCs. Examin-
ing the CD4+ T cell response, it was evident that transfer of 
HDM-pulsed CD103+ DCs mainly led to the generation of 
IFN-γ–producing CD4+ T cells, whereas CD11b+ DCs in-
duced predominant Th2 and weaker Th1 and Th17 responses 
(Fig. 8 D). Both Th2 and Th17 CD4+ T cell polarization was 
strongly dependent on the DC-intrinsic presence of PPARγ 
because, in its absence, IL-4–, IL-5–, and IL-17A–produc-
ing cells were significantly reduced, whereas the number of 
IFN-γ+ cells was unaffected (Fig. 8 D). Collectively, these re-
sults suggested that, although PPARγ regulates DC-induced 
T helper cell polarization in both lung-resident, conven-
tional DC subsets, in vivo it is mainly the CD11b+ subset 
that is strongly dependent on PPARγ for induction of potent 
type-2 immune responses.
IL-33 receptor and IL-4 receptor signaling controls PPArγ 
expression and th2 polarization
Having observed a major connection between IL-33 and 
PPARγ in regulating Th2 function, we were interested in 
examining whether IL-33 might also have a role in regu-
lating PPARγ in lung DCs. For that purpose, we measured 
PPARγ expression in lung DC subsets in naive WT and 
Il1rl1−/− animals. Interestingly, we found that PPARγ expres-
sion (i.e., MFI) was slightly reduced in lung CD11b+ DCs 
but not in CD103+ DCs from Il1rl1−/− mice (Fig. 9 A). To 
address the impact of blocked IL-33 receptor signaling on 
lung DC-mediated priming of naive T cells generally, lung 
DCs from naive WT and Il1rl1−/− animals were sorted and 
co-cultured with Smarta-1 transgenic T cells. Indeed, the fre-
quency of IL-4+ CD4+ T cells was reduced if the CD11b+ 
and CD103+ DC lacked IL-33 receptor signaling, whereas no 
significant difference could be observed for IFN-γ (Fig. 9 B). 
As ST2 was found to be dispensable for splenic, DC-mediated 
T cell priming in this assay (Fig. 3 F), we wanted to evalu-
ate whether differences in ST2 expression between lung and 
splenic DCs could explain that discrepancy. Indeed, we found 
only a small fraction of splenic DCs express the IL-33 recep-
tor (Fig. 9 C). Conversely, lung DCs exhibited a significantly 
higher proportion of ST2+ cells (Fig. 9 C).
IL-4 receptor signaling has been shown to induce 
PPARγ in macrophages (Szanto et al., 2010); therefore, we 
hypothesized that, in the context of allergic inflammation, that 
might also be the case in lung DCs. To address that question 
we initially analyzed the cytokine production of lung-resident 
cells in naive and HDM-injected WT animals. Indeed, we 
found that already in the steady-state a significant fraction of 
ILC2s produces IL-4, IL-5, and IL-13 and that, for IL-4 in 
particular, a significant increase in the frequency of IL-4+ cells 
can be observed after HDM administration (Fig. 9 D). Simi-
larly, basophils were also found to express significant levels of 
IL-4 but not IL-13 in the steady state, but that was not further 
enhanced after HDM injection (Fig. 9 E). Having established 
the presence of IL-4– and/or IL-13–producing cells in both 
naive and HDM-treated lungs, we were interested to examine 
the lung DC compartment in animals devoid of IL-4 receptor 
signaling. For that purpose, we analyzed PPARγ expression 
in Il4r−/− animals, which cannot respond to IL-4 or IL-13 
(Noben-Trauth et al., 1997). Indeed, we found that both 
CD11b+ and CD103+ DCs from Il4r-deficient animals ex-
hibited a strongly reduced level of PPARγ expression in the 
steady state (Fig.  9 F). Furthermore, when these cells were 
co-cultured with transgenic CD4+T cells, we observed a sig-
nificant reduction in type-2 cytokine, but not IFN-γ–pro-
ducing cells, for both lung DC subsets (Fig. 9 G).
Overall, these results suggested that both IL-33 and IL-4 
receptor signaling has a role in regulating PPARγ and DC 
capacity to promote Th2 priming.
dIscussIon
Dysregulated type-2 immune responses are responsible for 
some of the most-common, chronic inflammatory diseases, 
and to date, no therapies with high specificity and efficacy 
are available for treatment of conditions, such as asthma (Tan 
et al., 2016). This is also because the underlying molecular 
mechanisms remain incompletely understood. Here, we re-
port that the transcription factor PPARγ regulates pulmonary 
type-2 immunity at multiple levels, including the initiation 
and the exacerbation stage. We show that PPARγ is highly 
and specifically expressed in both mouse and human Th2 
cells, as opposed to other Th subsets. Indeed, we demon-
strate that PPARγ, although having only a minor direct role 
in regulating Th2 differentiation, controls Th2 sensitivity to 
IL-33 and, thus, has a major impact on Th2 effector function 
in vivo. In this context, mice lacking PPARγ exclusively in 
T cells develop reduced type-2 inflammatory responses in 
different models of pulmonary allergic inflammation. Both 
pulmonary eosinophilia and mucus production were found 
CXCR3+CCR6+CCR4– (enriched in Th1* cells); and CCR4+CCR6+CXCR3– (enriched in Th17 cells). (A and B) Representative dot plots of the cytokine production 
of the different T cell clone types analyzed from an allergic donor after restimulation with PMA/ionomycin (A) and a summary of all clones tested for that 
donor (B). (C–F) mRNA expression of PPA RG-1 and PPA RG-2 of two allergic (IgE+; C and D) and two non-allergic (IgE−; E and F) donor-derived clones after 
restimulation with PMA/ionomycin.(G and H) mRNA expression of PPA RG-1 (G) and PPA RG-2 (H) of memory T cell subsets sorted directly ex vivo from 
PBMCs. Data are means ± SEM, and the sample size is visible in each graph. ANO VA (one-way) was used. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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Figure 5. PPArγ in cd11c+ cells intrinsically mediates pulmonary allergic inflammation. (A–D) Ppargfl/fl and Cd11c-CrePpargfl/fl mice were sensitized 
and challenged intratracheally (i.t.), as indicated in the scheme with HDM extract. Total cell numbers in the BAL of eosinophils, neutrophils and AMs (B), 
CD4+ and CD8+ T cells (C), and the total amount of IgE in the BAL (D; n = 5/group). (E–G) WT and Cd11c-CrePpargfl/fl mice sensitized with OVA/alum i.p. and 
challenged i.t. A scheme of the immunization protocol (E); total cell numbers in the BAL of eosinophils, neutrophils, and AMs (F); and the total number of 
CD4+ T cells in the BAL (G; n = 5/group). (H–K) AMs were depleted with clodronate before HDM sensitization and challenge, as depicted in the scheme (H). 
The number of lung eosinophils and neutrophils (I) and CD4+ and CD8+ T cells (J). (K) Depicted is the frequency of cytokine-producing cells of CD4+ T cells 
after restimulation with PMA/ionomycin (n = 4/group). The data are representative of two experiments each and are means ± SEM, with the sample size (n). 
The Student’s t test (unpaired) was used. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.
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Figure 6. PPArγ in dcs modulates th2 polarization in vivo. (A) The generation of Cd11c-CrePpargfl/fl mice containing WT AMs is shown schemat-
ically. Fetal (E17.5) lung AM precursors from WT CD45.1+ C57BL/6 embryos were transferred intranasally to neonatal (day 3 after birth) Ppargfl/fl and 
Cd11c-CrePpargfl/fl mice. After 8 wk, animals showed a reconstitution of Cd11c-CrePpargfl/fl mice with mature WT AMs, and they were subsequently used in 
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to be strongly reduced in T cell–specific PPARγ KO ani-
mals. More specifically, we found PPARγ directly controlled 
IL-5 production and, more importantly, ST2 expression in 
vitro and in vivo. IL-33 receptor signaling has been shown to 
strongly promote Th2 effector function (Schmitz et al., 2005), 
and indeed, we found that IL-33, in conjunction with IL-4, 
strongly promoted IL-5 and ST2 expression, compared with 
IL-4 alone, suggesting the existence of a positive feedback 
loop between the IL-33 receptor stimulation and ST2 ex-
pression levels. Likely the lack of ST2 induction in vivo in 
PPARγ-deficient T cells is responsible for the general impair-
ment of Th2 effector function observed in allergic inflamma-
tion because PPARγ appears to have a significant, but only 
minor, direct role in regulating IL-4 expression. In addition, 
the observation that pharmacologic blockade of PPARγ in 
differentiated Th2 cells significantly inhibited effector cy-
tokine production suggests that PPARγ is more important 
in maintenance of effector function than in Th2 differentia-
tion by itself. Indeed, this observation was corroborated with 
human data, in which PPA RG expression was found to be 
particularly high in CRTh2+ Th2 cells, which also express 
high levels of IL-5, and only marginally higher levels of IL-4 
compared with CRTh2− Th2 cells. This suggests that, in hu-
mans, PPARγ has mainly a role in these “pathogenic” Th2 
cells, as opposed to all Th2 cells. As pharmacologic inhibition 
of PPARγ in differentiated Th2 cells was able to significantly 
attenuate their capacity to secrete type-2 cytokines, which 
suggests a potential therapeutic target for human therapy. This 
is in line with recent evidence that some polymorphisms in 
PPA RG in humans are associated with increased risk of de-
veloping asthma (Li et al., 2015).
In addition to controlling Th2 effector responses in vivo 
intrinsically in T cells, we found PPARγ also regulates the 
ability of lung-resident CD11b+ DCs to induce Th2 immu-
nity in vitro and in vivo. How DCs induce distinct T helper 
cell effector profiles and how different subsets contribute to 
the generation of the large diversity of different T cell re-
sponses in vivo has been intensely investigated in recent years 
(Kopf et al., 2015), and our results identify PPARγ as a new 
lung DC-intrinsic regulator of type-2 immunity. We found 
PPARγ to modulate the ability of CD11b+ DCs for antigen 
transport to the lung dLN in the context of HDM-induced 
inflammation, as well as in prime, naive CD4+ T cells to-
ward Th2 polarization. Indeed, the requirement for PPARγ 
in CD11b+ DCs to induce potent Th2 effector responses in 
vivo, likely represents a combined effect of these two defi-
ciencies. Indeed, these results also confirm CD11b+ DCs as 
the main drivers of type-2 inflammation in the HDM model 
(Plantinga et al., 2013). Interestingly, we found that, similar to 
T cells, PPARγ links CD11b+ DC-mediated Th2 immunity 
to the epithelium-derived cytokine IL-33. Recent evidence 
shows that IL-33 promotes DC-mediated Th2 priming in 
HDM-induced inflammation, and it appears that it directly 
controls PPARγ expression in DCs in vivo (de Kleer et al., 
2016). Indeed, we could confirm the notion that the lack of 
IL-33 receptor signaling impairs the capacity of lung CD11b+ 
DCs to prime Th2 cytokine production. Interestingly, this 
was not the case for splenic DCs. Likely this can be explained 
by the much lower frequency of ST2+ DCs in the spleen 
compared with the lung. These results, therefore, highlight the 
specific importance of IL-33 in lung immunity. In addition to 
the role of IL-33 in regulating PPARγ in lung CD11b+ DCs, 
we found it to strongly depend on IL-4 receptor signaling. 
IL-4 receptor–deficient lung CD11b+ DCs were found to 
have impaired capacity to prime naive CD4+ T cells toward 
Th2, which is line with the notion that IL-4 can promote 
lung DC-mediated Th2 priming (Webb et al., 2007). Thus, it 
appears that PPARγ integrates multiple tissue– and immune 
cell–derived, external cues to promote induction of Th2 im-
munity by lung-resident CD11b+ DCs. The transcriptional 
program in lung CD11b+ DCs controlled by PPARγ to pro-
mote Th2 polarization likely involves regulation of lipid me-
tabolism, and indeed, this link has been suggested to explain 
some of the effects observed in in vitro–derived mouse and 
human DCs using PPARγ-activating ligands (Klotz et al., 
2007; Szatmari et al., 2007). Collectively, the results presented 
in this article establish PPARγ as a potent proinflammatory 
factor in type-2 immunity by acting as a sensor for multi-
ple, external signals in regulating the interaction between T 
cells and DCs during the induction and promotion of aller-
gic lung inflammation. Indeed, they strongly contrast with 
the current view of this transcription factor as being more 
anti-inflammatory (Croasdell et al., 2015). These earlier con-
clusions were largely based on studies administering synthetic 
PPARγ agonists (i.e., thiazolidinediones) in different exper-
imental models of asthma (Trifilieff et al., 2003; Woerly et 
al., 2003; Zhao et al., 2014). Aside from the possibility that 
the effects observed in earlier studies could be explained by 
off-target effects of PPARγ agonists (Nemenoff, 2007; Sauer, 
2015), this discrepancy could also suggest that, in addition 
HDM or OVA/alum asthma protocols, as described in Fig. 1 and Fig. S1. (B) Animals were sensitized with HDM and challenged with HDM or PBS with total 
cell numbers in the BAL (B) and lung (C) of eosinophils and neutrophils (n = 4–8/group). (D, left) Hematoxylin and eosin (H&E) histology. (D, right) PAS and 
Alcian blue histology. (E) Representative sections of total cell numbers of CD4+ and CD8+ T cells in the BAL. (F) BAL CD4+ T cells were restimulated with 
PMA/ionomycin for 4 h, and intracellular cytokine production was quantified, with the frequency of indicated cytokines (n = 4–8/group). (G) Total number 
of lung ILC2s are shown. (H–J) WT and Cd11c-CrePpargfl/fl mice were sensitized with OVA/alum i.p. and challenged with OVA intratracheally (H). Shown are 
total cell numbers in the lung of eosinophils and neutrophils (I) and CD4+ and CD8+ T cells (J). (J) BAL CD4+ T cells were restimulated with PMA/ionomycin 
for 4 h, and intracellular cytokine production was quantified. Frequency of IFN-γ+, IL-17A+, and IL-4+ cells as well as the MFI for IL-4 (n = 5/group). The data 
are representative of two experiments for each panel and are means ± SEM, with the sample size (n). The Student’s t test (unpaired) was used. *, P < 0.05; 
**, P < 0.01; ****, P < 0.0001.
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to a role in T cells and DCs, PPARγ may have opposing 
functions in other cell types. Indeed, PPARγ is expressed by 
lung epithelial cells (Honda et al., 2004) and also by other 
lung-resident, immune cell types, such as ILC2s (Robinette 
et al., 2015). The cell-type–specific roles of PPARγ in these 
cell types remain to be elucidated. In summary, our results 
establish PPARγ as an important driver of lung type-2 im-
mune responses by regulating the interaction between DCs 
and CD4+ T cells and acting as an integrator of immune cell– 
and tissue-derived signals to control induction and promo-
tion pulmonary allergic inflammation.
MAterIALs And MetHods
Mice
Ppargfl/fl mice (Imai et al., 2004) were backcrossed for eight 
generations to C57BL/6 before crossing them to Tg(Itgax- 
cre)1-1Reiz (Cd11c-Cre) mice (Caton et al., 2007) or Cd4-
cre mice (Wolfer et al., 2001) to generate mice with defi-
Figure 7. PPArγ is largely dispensable for lung dc activation and antigen uptake but mediates antigen transport by cd11b+ dcs to the dLn. 
WT and AM-reconstituted Cd11c-CrePpargfl/fl were injected intratracheally with 100 µg OVA-AF488 and 100 µg HDM and sacrificed 24 h later for analysis 
of lung and dLNs by flow cytometry. DC subsets were identified as CD45+ Siglec-F−CD11c+MHC IIhigh for the lung and CD45+autofluorescent−CD11c+MHC 
IIhigh for the lung and dLNs, respectively. Frequency of OVA-AF488+ among each DC subset in the lung dLN (A) and the total number of OVA-AF488+ DCs (B). 
Frequency of OVA-AF488+ among each DC subset in the lung (C) and the total the total number of OVA-AF488+ DCs (D). MFIs of indicated DC activation 
markers for lung dLN (E–G) and lung (H–J) DC subsets as a summary of FACS data. (K and L) MFI of ST2-expressing cells among DCs in the lung (K) and the 
lung dLN (L; n = 4–6/group). The data are representative of two experiments and are means ± SEM. The Student’s t test (unpaired) was used. *, P < 0.05.
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ciency in PPARγ in CD11c+ cells (Cd11c-CrePpargfl/fl) and 
T cells (Cd4-CrePpargfl/fl), respectively. Gt(ROSA)26Sortm-
1Hjf (Rosa26fl/fl-RFP) mice (Luche et al., 2007) were crossed 
with Cd11c-Cre and Cd4-Cre mice. OT-II mice (JAX 
004194; The Jackson Laboratory), Smarta-1 mice (Oxenius 
et al., 1998), and Il4r−/− mice (Barner et al., 1998). All mice, 
including C57BL/6J WT mice, were either bred and main-
tained in individually ventilated cages under specific patho-
gen-free conditions at ETH Phenomics Center, except the 
Il1rl1−/− mice (Townsend et al., 2000), which were provided 
by D. Pinschewer (University of Basel, Basel, Switzerland). 
For all strains expressing Cre, littermate controls were used, 
whereas for other experiments, C57BL/6J mice were used as 
controls. Mice used for experiments were between 6 and 14 
wk old, unless otherwise stated. All animal experiments were 
approved by the local animal ethics committee (Kantonales 
Veterinaersamt Zurich) and were performed according to 
local rules [Swiss Animal Protection Ordinance (TschV), Zu-
rich, Switzerland] and Swiss animal protection law (TschG).
cell suspension preparations
Mice were sacrificed by an overdose of sodium pentobarbital 
by i.p. injection. Organs were removed and then processed 
according to the following procedure: spleens and LNs were 
minced and then digested with 2 mg/ml of type IV colla-
genase (Worthington) and 0.02 mg/ml DNaseI (Sigma) at 
37°C for 45 min and subsequently passed through a 70-µm 
cell strainer. Lungs were digested with 1 mg/ml hyaluronidase 
Figure 8. PPArγ in dcs intrinsically controls th2 polarization. Lung DCs from Ppargfl/fl and Cd11c-CrePpargfl/fl mice, which had been reconstituted with 
WT AMs were sorted and cultured in vitro for 4 d with OTII cells and 10 nM OVA323-339 peptide. Frequency of IL-4+, IFNγ+ and IL-17A+ CD4+ T cells (A) and the 
proliferation of efluor-670 labeled OTII cells (B; n = 3/condition) are shown. (C and D) Ppargfl/fl and Cd11c-CrePpargfl/fl mice, which had been reconstituted 
with WT AMs were injected with 100 µg HDM. 24 h after infection, the lung conventional DC subsets of each genotype were sorted and transferred intra-
tracheally to naive WT recipients. After 10 d, those animals were challenged for a consecutive 5 d with 10 µg HDM and were subsequently analyzed on day 
17. Total number of eosinophils and neutrophils (C) and the total numbers of cytokine producing CD4+ T cells in the BAL (D; n = 5/group). Data are means ± 
SEM and the sample size (n) and are representative of two independent experiments. ANO VA (one-way) was used. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
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Figure 9. IL-4 receptor and IL-33 receptor signaling controls PPArγ expression and dc-mediated th2 polarization. (A) PPARγ expression in lung 
DCs from naive WT and Il1rl1−/− mice was measured using flow cytometry. Shown is the MFI of PPARγ normalized to the PPARγ-deficient control of the 
indicated DC subsets (n = 3/group). (B) Lung DCs from WT and Il1rl1−/− animals were isolated and co-cultured in vitro for 4 d with naive, splenic, Smarta-1, 
transgenic CD4+ T cells and 1 nM gp61 peptide. Frequency of IL-4+ and IFN-γ+ CD4+ T cells (n = 10/condition). (C) Surface expression of ST2 on WT lung 
and splenic DCs was evaluated using flow cytometry. Shown are representative FACS plots including fluorescence minus one (FMO) controls (n = 3/group). 
(D and E) WT animals received PBS or 100 µg HDM intratracheally and lungs were analyzed for cytokine-producing cells 18 h after infection. Shown is the 
frequency of cytokine-producing ILC2s (D) and basophils (E) of indicated cytokines (n = 4/group). (F) PPARγ expression in lung DCs from naive WT and 
Il4ra−/− mice was measured using flow cytometry. Shown is the MFI of PPARγ normalized to the PPARγ-deficient control of the indicated DC subsets (n = 3/
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(Sigma), 25 µg/ml collagenase XI (Sigma), 50 µg/ml Liberase 
TM (Roche), and 0.02 mg/ml DNaseI (Sigma) at 37°C for 
45 min and subsequently passed through a 70-µm cell strainer. 
ACK buffer was used for erythrocyte lysis for all organs.
Flow cytometry
Multiparameter analysis was performed on a FAC SCanto II 
or LSR Fortessa (BD) and analyzed with FlowJo software 
(Tree Star). Fluorochrome-conjugated or biotinylated mAbs 
specific to mouse CD11c (N418), CD11b (M1/70), SiglecF 
(E50−2440; BD Biosciences), CD103 (2E7), CD45 (30-
F11), CD45.2 (104), CD4 (GK1.5), CD8α (53-6.7), MHC 
class II (M5/114.15.2; eBioscience), CD64 (X54-5/7.1), 
CD19 (6D5), CD3e (145-2C11), CD127 (A7R34), CD90.2 
(30-H12), TCR-β (H57-597) NK1.1 (PK136, eBiosci-
ence), ST2 (DIH9), CD25(PC61), GITR (DTA-1) FcεRIα 
(MAR-1; eBioscience), XCR1 (ZET), Ly-6G (1A8-Ly6g), 
IL-4 (11B11), IL-5 (TRFK5), GATA3 (TWAJ; eBioscience), 
RORγt (AFK JS-9; e Bioscience), IL-17A (eBio17B7; eBio-
science), IL-13 (eBio13A; eBioscience), IFN-γ (XMG1.2), 
IL-22 (IL22JOP; eBioscience), IL-17F (SHLR17; eBiosci-
ence) were purchased from BioLegend unless otherwise 
stated. For intracellular staining of transcription factors, cells 
were fixed and stained using the intracellular fixation and 
permeabilization kit (eBioscience) according to the manu-
facturer’s instructions. PPARγ was stained using monoclo-
nal rabbit anti-PPARγ (81B8; Cell Signaling Technology), 
followed by staining with goat anti–rabbit IgG antibodies 
(Invitrogen). Dead cells were excluded using the live/dead 
marker eFluor780 (eBioscience). Before all staining, FcγIII/
II receptors were blocked by incubation with homemade 
anti-CD16/32 (2.4G2). Annexin V on apoptotic cells was 
stained using the Annexin V detection kit (eBioscience) ac-
cording to the manufacturer’s instructions. eFluor 670 prolif-
eration dye (eBioscience) and CFSE (eBioscience) were used 
according to the manufacturer’s instructions.
Mouse models of airway inflammation
For the OVA model, animals were injected i.p. with 100 
µg OVA (Invitrogen) resuspended in aluminum hydroxide 
solution (Serva). At the indicated times, animals were chal-
lenged with intratracheal injection of 20 µg of OVA in PBS. 
For the HDM model, animals received either 10 µg or 50 
µg HDM (Greer) intratracheally for sensitization and were 
then challenged at the indicated times with either 10 µg or 
20 µg HDM extract, depending on the set of experiments 
and on the batch of HDM used. The HDM batches were 
standardized for their activity in vivo to allow comparison of 
experiments with different batches, and the amounts used are 
indicated in each figure.
dc–t cell co-culture
DCs were sorted from processed organs as described in Cell 
suspension preparations. CD4+ T cells were obtained with 
CD4 MACS-bead (Miltenyi) pre-enrichment and subse-
quent to FACS-sorting from naive splenocytes. CD4+ T 
cells were sorted as CD4+CD11c− autofluorescent-negative 
cells. T cells and DCs were then cultured together for 4 d 
in complete IMDM medium (Life Technologies). For cul-
tures using OTII cells varying concentrations of OVA323-339 
peptide (Mimotopes Australia) was added. For cultures using 
Smarta-1 CD4+ T cells, varying concentrations of Gp61-80 
(Mimotopes Australia) peptide was added. For cultures using 
Ppargfl/fl and Cd4-CrePpargfl/fl animals, plates were coated 
with 2 µg/ml αCD3. For in vitro polarizing conditions 
the following setup was used: Th0 was medium only; Th1 
was 20 ng/ml IL-12; Th2 was 100 ng/ml IL-4 + 20 µg/
ml αIFN-γ; Th17 was 1 ng/ml TGF-β1 + 50 ng/ml IL-6 + 
20 µg/ml αIFN-γ; and Th22 was 20 ng/ml IL-6 + 20 ng/
ml IL-23. For co-cultures with IL-33, all samples were cul-
tured with 20 µg/ml αIFN-γ, 100 ng/ml IL-4, 100 ng/ml 
IL-33, or 100 ng/ml IL-4 + 100 ng/ml IL-33,respectively. 
Before flow cytometric analysis, cells were restimulated 
with PMA (Sigma)/ionomycin (Sigma) in the presence 
of monensin (Sigma). For the cultures using PPARγ an-
tagonist GW9962 (Sigma), cells were either cultured in the 
presence of the inhibitor from the beginning, with analysis 
after 4 d, or the inhibitor was added after 4 d of culture for 
24 h together with αCD3.
treg suppression assay
Treg cells were sorted as CD4+CD25+GITR+ T cells after 
MACS-bead (Miltenyi) pre-enrichment from the indicated 
organs. Treg cells were then cultured at the indicated ratios 
to naive T cells in the presence of splenic DCs and αCD3. 
Proliferation of effector T cells was evaluated on day 3 and 
cytokine production on day 4 of co-culture.
Antibody eLI sA
At the indicated times, BAL fluid was measured for HDM- 
specific IgE antibody isotype or cytokine levels. For HDM- 
specific IgE, 96-well plates (Maxisorp; Nunc) were coated 
with HDM in PBS overnight at 4°C. Plates were washed and 
incubated with PBS-1% BSA for 2 h at room temperature for 
blocking. Samples from BAL fluids were incubated at room 
temperature for 2 h. Plates were then washed five times. For 
IgE, plates were then incubated with alkaline–phosphate-la-
beled goat anti–mouse antibodies to IgE (SouthernBio-
tech Technologies, Inc.) at a 1:1,000 dilution in PBS-0.1% 
BSA at room temperature for 2 h. Subsequently, plates were 
washed five times, and substrate p-nitrophenyl phosphate 
group). (G) Lung DCs from WT and Il4ra−/− animals were isolated and co-cultured in vitro for 4 d with naive, splenic, Smarta-1, transgenic CD4+ T cells and 
1 nM gp61 peptide. Shown are the frequencies of IL-4+, IL-5+, IL-13+, and IFN-γ+ CD4+ T cells (n = 8/condition) Data are means ± SEM and the sample size 
(n). ANO VA (one way) was used. *, P < 0.05; **, P < 0.01.
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(Sigma) was added. ODs were measured on an ELI SA reader 
(Bucher Biotec) at 405 nm.
dc-mediated antigen uptake and transport
Animals received 100 µg OVA-AlexaFluor488 (Invitrogen) 
and 100 µg HDM (Greer) intratracheally. Lungs and dLNs were 
collected 24 h after infection and analyzed by flow cytometry.
clodronate treatment
For the depletion of AMs, mice were treated with 100  µl 
clodronate liposomes intratracheally 2 d before sensitization 
with HDM. Clodronate was a gift from Roche. Control mice 
were treated with PBS liposomes.
Bone marrow chimeras
For BM chimeras, C57BL/6 CD45.2+ mice were lethally ir-
radiated (9.5 gray, using a cesium source) and reconstituted 
with 5–10 × 106 BM cells of the background and with the 
ratio indicated for each experiment. Mice were analyzed 10 
wk after reconstitution.
transfer of AM precursors into neonates
Lungs from E17.5 embryos from CD45.1+ WT animals were 
harvested, minced, and digested with collagenase IV as de-
scribed above in Cell suspension preparations. CD45+ cells 
were then purified using MACS beads (Miltenyi), and cells 
were then transferred intranasally into day 1–7 postbirth ne-
onates to allow reconstitution of a WT AM compartment.
Quantitative real-time Pcr
For analysis of mRNA expression, RNA was isolated from 
cells with TRIzol reagent (Invitrogen) and was reverse-tran-
scribed with GoScript reverse transcription according to the 
manufacturer’s instructions (Promega). Quantitative real-time 
RT-PCR was performed with Kapa SYBR Fast. For human 
samples, the expression of PPA RG-1 (forward primer: 5′-
AAA GAA GCC GAC ACT AAA CC-3′ and reverse primer: 
5′-CTT CCA TTA CGG AGA GAT CC-3′) and PPA RG-2 
(forward primer: 5′-AGG CGA GGG TCT TGA CAG-3′ and 
reverse primer: 5′-GAT GCG GAT GGC CAC CTC TTT-3′) 
were normalized to that of housekeeping gene TBP (for-
ward primer: 5′-TTG ACC TAA AGA CCA TTG CAC TTC-
3′ and reverse primer: 5′-TGT TCT TCA CTC TTG GCT 
CC-3′). For mouse samples, Pparg (forward primer: 5′-GTG 
ATG GAA GAC CAC TCG CATT-3′ and reverse primer: 5′-
CCA TGA GGG AGT TAG AAG GTTC-3′) expression was 
normalized to Tbp (forward primer: 5′-TTG ACC TAA 
AGA CCA TTG CAC TTC-3′ and reverse primer: 5′-TTC 
TCA TGA TGA CTG CAG CAAA-3′).
Human blood samples
Blood samples were obtained from the Swiss Blood Dona-
tion Center and from allergic donors. All blood donors pro-
vided written, informed consent forms approved by the ethics 
committee of Canton of Ticino before inclusion in this study. 
Human primary cell protocols were approved by the Federal 
Office of Public Health (authorization. A000197/2 to F. Sal-
lusto). IgE concentration in plasma was measured by ELI SA.
Isolation of human t cell clones and HdM-reactive t cells
PBMCs were isolated with Ficoll-Paque Plus (GE Health-
care). CD4+ T cells were isolated by positive selection with 
CD4 magnetic micro-beads (Miltenyi Biotec). CD4+ T cells 
were then stained with the following mAbs: anti–CD4-PE 
Texas Red (S3.5), anti–CD45RA-QD655 (MEM-56; Invit-
rogen), anti–CCR7-Brilliant Violet 421 (G043H7), anti–CX-
CR3-Alexa Fluor 647 (G025H7; BioLegend), anti–CCR6-PE 
(11A9), anti–CCR4-PE-Cy7 (1G1), anti–CRTh2-FITC 
(BM16; BD), anti–CD8-PE-Cy5 (B9.11), anti–CD14-
PE-Cy5 (RMO52), anti–CD19-PE-Cy5 (J3-119), anti–
CD25-PE-Cy5 (B1.49.9), and anti-CD56-PE-Cy5 (N901; 
Beckman Coulter). CD4+ effector memory T cell subsets 
were FACS-sorted (FAC SAria III; BD) as follows and after 
gating on CD4+CD8–CD14–CD19–CD25–CD56–CD45RA–
CCR7– cells: CRTh2+CCR4+CXCR3–CCR6– (enriched in 
inflammatory Th2 cells); CCR4+CRTh2–CXCR3–CCR6– 
(enriched in Th2 cells); CXCR3+CCR4–CCR6– (enriched 
in Th1 cells); CXCR3+CCR6+CCR4– (enriched in Th1* 
cells); CCR4+CCR6+CXCR3– (enriched in Th17 cells; Messi 
et al., 2003; Acosta-Rodriguez et al., 2007). To obtain T cell 
clones, T cells from each subset were plated at 0.5 cells/well 
in 384-well plates in RPMI-1650 complete medium (2 mM 
glutamine, 1% nonessential aa, 1% sodium pyruvate, 50 µM 
2-mercaptoethanol, 1% penicillin/streptomycin [all from Life 
Technologies] and 5% human serum [Swiss Red Cross]) in 
the presence of 1 µg/ml PHA (Remel), irradiated allogeneic 
PBMCs (2.5 × 104 per well), and 500 IU/ml IL-2. T cell 
clones were grown in IL-2–containing RPMI-1650 complete 
medium and used on day 18–20 after initial stimulation. For 
the analysis of HDM-reactive T cell subsets sorted from the 
blood of HDM-IgE+ donors were cultured at a ratio of 2:1 
with irradiated autologous monocytes prepulsed for 5 h with 
30 µg/ml HDM extract (Greer). On day 6, activated T cells 
were sorted as ICOS+CD25+ after staining with anti-ICOS–
Pacific Blue (C398.4A) and anti-CD25–Brilliant Violet 785 
(BC96; BioLegend) mAbs and analyzed immediately or after 
expansion in IL-2–containing complete medium.
Analysis of human t cells
T cell clones and HDM-reactive T cells were screened for 
their cytokine expression profile by intracellular cytokine 
staining. Cells were stimulated with 0.2  µM PMA (Sigma) 
and 1 µg/ml ionomycin (Sigma) for 5 h in RPMI-1640 com-
plete medium. Brefeldin A (Sigma) was added at 10 µg/ml 
after 2.5 h of stimulation. T cells were stained with Live/Dead 
Fixable Aqua Dead Cell Stain kit (Life Technologies, Molec-
ular Probes). T cells were then fixed and permeabilized with 
Cytofix/Cytoperm (BD), according to the manufacturer’s 
instructions, and stained with IL-4-Alexa Fluor 488 (8D4-
8; eBioscience), IL-5-APC (TRFK5; BD), IL-17-Brilliant 
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Violet 605 (BL168), and IFN-γ-Brilliant Violet 650 (4S.B3; 
BioLegend). PPAR-γ mRNA expression was measured by 
quantitative PCR on 5 × 105 T cells, resting or stimulated 
for 4 h with 0.2 µM PMA and 1 µg/ml ionomycin, or for 
4 h and 16 h with immobilized anti-CD3 (Lanzavecchia and 
Scheidegger, 1987; TR66) and anti-CD28 (CD28.2) mAbs 
(BD), both at 1 µg/ml, in RPMI-1640 complete medium.
Histology
Mouse lungs from HDM-treated animals were removed and 
fixed in 4% formalin. Subsequently, they were processed and 
then stained with either hematoxylin and eosin or periodic 
acid–Schiff and Alcian blue.
rnA sequencing
Indicated cells were collected into TRIzol (Life Technologies), 
phase separation was achieved with the addition of chloroform 
(Sigma), and RNA was precipitated from the aqueous layer 
with isopropanol (Sigma) using glycogen (Roche) as a carrier. 
The TruSeq RNA Stranded sample kit (Illumina) was used to 
construct the sequencing libraries. In brief, total RNA samples 
(100 ng) were poly(A)-enriched and reverse-transcribed into 
double-stranded cDNA. TruSeq adapters were then ligated to 
double-stranded cDNA. Fragments containing TruSeq adapt-
ers on both ends were selectively enriched with PCR and 
were subsequently sequenced on the Illumina NextSeq 500 
in single-end mode, 150 cycles, at the Functional Genomics 
Center Zurich (GEO accession no. GSE100588).
statistical analysis
Means, SDs, SEMs, Student’s t test (unpaired), and ANO VAs 
(one-way) were calculated with Prism software (Graph-
Pad Software). *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
****, P < 0.0001.
online supplemental material
Fig. S1 shows that PPARγ in T cells mediates development 
of pulmonary allergic inflammation in an OVA/alum model 
and is not required for Treg suppressive capacity in vitro. Fig. 
S2 shows that PPARγ is highly expressed in human effector 
memory Th2 cells. Fig. S3 shows that PPARγ is required for 
terminal differentiation of AMs. Fig. S4 shows that intratra-
cheal administration of clodronate specifically depletes AMs.
AcknowLedgMents
We acknowledge the use of the ImmGen database as an informative tool for the 
design of this study. We thank Franziska Ampenberger for technical assistance.
We thank Schweizerischer Nationalfonds zur Förderung der Wissenschaf-
tlichen Forschung (grants 310030B and 141175) and Eidgenössische Technische 
Hochschule Zürich (grant 34/13-1) for supporting this study. This work was also 
partially supported by European Research Council (grant 323183, PRE DICT, to 
F. Sallusto).
The authors declare no competing financial interests.
Author contributions: S.P. Nobs, S. Natali, and K. Okreglicka performed the 
experiments; S.P. Nobs, S. Natali, L. Pohlmeier, K. Okreglicka, and M. Kurrer analyzed 
data; S.P. Nobs, C. Schneider, F. Sallusto, and M. Kopf designed the experiments; and 
S.P. Nobs and M. Kopf wrote the manuscript.
Submitted: 8 December 2016
Revised: 5 May 2017
Accepted: 10 July 2017
reFerences
Acosta-Rodriguez, E.V., L. Rivino, J. Geginat, D. Jarrossay, M. Gattorno, A. 
Lanzavecchia, F. Sallusto, and G. Napolitani. 2007. Surface phenotype 
and antigenic specificity of human interleukin 17-producing T helper 
memory cells. Nat. Immunol. 8:639–646. http ://dx .doi .org /10 .1038 /
ni1467
Barner, M., M. Mohrs, F. Brombacher, and M. Kopf. 1998. Differences 
between IL-4R α-deficient and IL-4-deficient mice reveal a role for 
IL-13 in the regulation of Th2 responses. Curr. Biol. 8:669–672. http ://
dx .doi .org /10 .1016 /S0960 -9822(98)70256 -8
Becattini, S., D. Latorre, F. Mele, M. Foglierini, C. De Gregorio, A. Cassotta, 
B. Fernandez, S. Kelderman, T.N. Schumacher, D. Corti, et al. 2015. T 
cell immunity. Functional heterogeneity of human memory CD4+ T cell 
clones primed by pathogens or vaccines. Science. 347:400–406. http ://dx 
.doi .org /10 .1126 /science .1260668
Bouhlel, M.A., B. Derudas, E. Rigamonti, R. Dièvart, J. Brozek, S. Haulon, 
C. Zawadzki, B. Jude, G. Torpier, N. Marx, et al. 2007. PPARγ activation 
primes human monocytes into alternative M2 macrophages with anti-
inflammatory properties. Cell Metab. 6:137–143. http ://dx .doi .org /10 
.1016 /j .cmet .2007 .06 .010
Caton, M.L., M.R. Smith-Raska, and B. Reizis. 2007. Notch-RBP-J 
signaling controls the homeostasis of CD8− dendritic cells in the spleen. 
J. Exp. Med. 204:1653–1664. http ://dx .doi .org /10 .1084 /jem .20062648
Croasdell, A., P.F. Duffney, N. Kim, S.H. Lacy, P.J. Sime, and R.P. Phipps. 
2015. PPARγ and the innate immune system mediate the resolution 
of inflammation. PPAR Res. 2015:549691. http ://dx .doi .org /10 .1155 
/2015 /549691
de Kleer, I.M., M. Kool, M.J. de Bruijn, M. Willart, J. van Moorleghem, 
M.J. Schuijs, M. Plantinga, R. Beyaert, E. Hams, P.G. Fallon, et al. 2016. 
Perinatal activation of the interleukin-33 pathway promotes type 2 
immunity in the developing lung. Immunity. 45:1285–1298. http ://dx 
.doi .org /10 .1016 /j .immuni .2016 .10 .031
Gregory, L.G., and C.M. Lloyd. 2011. Orchestrating house dust mite-
associated allergy in the lung. Trends Immunol. 32:402–411. http ://dx 
.doi .org /10 .1016 /j .it .2011 .06 .006
Hammad, H., H.J. de Heer, T. Soullié, V. Angeli, F. Trottein, H.C. Hoogsteden, 
and B.N. Lambrecht. 2004. Activation of peroxisome proliferator-
activated receptor-γ in dendritic cells inhibits the development of 
eosinophilic airway inflammation in a mouse model of asthma. Am. J. 
Pathol. 164:263–271. http ://dx .doi .org /10 .1016 /S0002 -9440(10)63116 
-1
Holt, P.G., J. Oliver, N. Bilyk, C. McMenamin, P.G. McMenamin, G. Kraal, 
and T. Thepen. 1993. Downregulation of the antigen presenting cell 
function(s) of pulmonary dendritic cells in vivo by resident alveolar 
macrophages. J. Exp. Med. 177:397–407. http ://dx .doi .org /10 .1084 /jem 
.177 .2 .397
Honda, K., P. Marquillies, M. Capron, and D. Dombrowicz. 2004. Peroxisome 
proliferator-activated receptor γ is expressed in airways and inhibits 
features of airway remodeling in a mouse asthma model. J. Allergy Clin. 
Immunol. 113:882–888. http ://dx .doi .org /10 .1016 /j .jaci .2004 .02 .036
Imai, T., R. Takakuwa, S. Marchand, E. Dentz, J.M. Bornert, N. Messaddeq, 
O. Wendling, M. Mark, B. Desvergne, W. Wahli, et al. 2004. Peroxisome 
proliferator-activated receptor γ is required in mature white and brown 
adipocytes for their survival in the mouse. Proc. Natl. Acad. Sci. USA. 
101:4543–4547. http ://dx .doi .org /10 .1073 /pnas .0400356101
Klotz, L., I. Dani, F. Edenhofer, L. Nolden, B. Evert, B. Paul, W. Kolanus, 
T. Klockgether, P. Knolle, and L. Diehl. 2007. Peroxisome proliferator-
activated receptor γ control of dendritic cell function contributes to 
PPARγ controls type-2 immunity | Nobs et al.3034
development of CD4+ T cell anergy. J. Immunol. 178:2122–2131. http ://
dx .doi .org /10 .4049 /jimmunol .178 .4 .2122
Klotz, L., S. Burgdorf, I. Dani, K. Saijo, J. Flossdorf, S. Hucke, J. Alferink, N. 
Nowak, M. Beyer, G. Mayer, et al. 2009. The nuclear receptor PPARγ 
selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and 
suppresses CNS autoimmunity. J. Exp. Med. 206:2079–2089 (published 
erratum appears in J. Exp. Med. 2009. 206:3159). http ://dx .doi .org /10 
.1084 /jem .20082771
Kopf, M., G. Le Gros, M. Bachmann, M.C. Lamers, H. Bluethmann, and G. 
Köhler. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine 
responses. Nature. 362:245–248. http ://dx .doi .org /10 .1038 /362245a0
Kopf, M., C. Schneider, and S.P. Nobs. 2015. The development and function 
of lung-resident macrophages and dendritic cells. Nat. Immunol. 16:36–
44. http ://dx .doi .org /10 .1038 /ni .3052
Kurowska-Stolarska, M., B. Stolarski, P. Kewin, G. Murphy, C.J. Corrigan, S. 
Ying, N. Pitman, A. Mirchandani, B. Rana, N. van Rooijen, et al. 2009. 
IL-33 amplifies the polarization of alternatively activated macrophages 
that contribute to airway inflammation. J. Immunol. 183:6469–6477. http 
://dx .doi .org /10 .4049 /jimmunol .0901575
Lambrecht, B.N., M. De Veerman, A.J. Coyle, J.C. Gutierrez-Ramos, K. 
Thielemans, and R.A. Pauwels. 2000. Myeloid dendritic cells induce 
Th2 responses to inhaled antigen, leading to eosinophilic airway 
inflammation. J. Clin. Invest. 106:551–559. http ://dx .doi .org /10 .1172 /
JCI8107
Lanzavecchia, A., and D. Scheidegger. 1987. The use of hybrid hybridomas to 
target human cytotoxic T lymphocytes. Eur. J. Immunol. 17:105–111. http 
://dx .doi .org /10 .1002 /eji .1830170118
Li, W., W. Dai, J. Sun, W. Zhang, Y. Jiang, C. Ma, C. Wang, and J. He. 2015. 
Association of peroxisome proliferator-activated receptor-γ gene poly-
morphisms and gene-gene interaction with asthma risk in a Chinese 
adults population. Int. J. Clin. Exp. Med. 8:19346–19352.
Luche, H., O. Weber, T. Nageswara Rao, C. Blum, and H.J. Fehling. 2007. 
Faithful activation of an extra-bright red fluorescent protein in 
“knock-in” Cre-reporter mice ideally suited for lineage tracing studies. 
Eur. J. Immunol. 37:43–53. http ://dx .doi .org /10 .1002 /eji .200636745
Messi, M., I. Giacchetto, K. Nagata, A. Lanzavecchia, G. Natoli, and F. Sallusto. 
2003. Memory and flexibility of cytokine gene expression as separable 
properties of human TH1 and TH2 lymphocytes. Nat. Immunol. 4:78–86. 
http ://dx .doi .org /10 .1038 /ni872
Nemenoff, R.A. 2007. Peroxisome proliferator-activated receptor-γ in lung 
cancer: Defining specific versus “off-target” effectors. J. Thorac. Oncol. 
2:989–992. http ://dx .doi .org /10 .1097 /JTO .0b013e318158cf0a
Noben-Trauth, N., L.D. Shultz, F. Brombacher, J.F. Urban Jr., H. Gu, and W.E. 
Paul. 1997. An interleukin 4 (IL-4)-independent pathway for CD4+ T 
cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc. 
Natl. Acad. Sci. USA. 94:10838–10843. http ://dx .doi .org /10 .1073 /pnas 
.94 .20 .10838
Nobs, S.P., C. Schneider, M.G. Dietrich, T. Brocker, A. Rolink, E. Hirsch, 
and M. Kopf. 2015. PI3-Kinase-γ has a distinct and essential role in 
lung-specific dendritic cell development. Immunity. 43:674–689. http ://
dx .doi .org /10 .1016 /j .immuni .2015 .09 .006
Ohnmacht, C., J.H. Park, S. Cording, J.B. Wing, K. Atarashi, Y. Obata, 
V. Gaboriau-Routhiau, R. Marques, S. Dulauroy, M. Fedoseeva, et al. 
2015. Mucosal immunology. The microbiota regulates type 2 immunity 
through RORγt+ T cells. Science. 349:989–993. http ://dx .doi .org /10 
.1126 /science .aac4263
Oxenius, A., M.F. Bachmann, R.M. Zinkernagel, and H. Hengartner. 1998. 
Virus-specific MHC-class II-restricted TCR-transgenic mice: effects 
on humoral and cellular immune responses after viral infection. Eur. 
J. Immunol. 28:390–400. http ://dx .doi .org /10 .1002 /(SICI)1521 
-4141(199801)28 :01<390::AID-IMMU390>3.0.CO;2-O
Plantinga, M., M. Guilliams, M. Vanheerswynghels, K. Deswarte, F. Branco-
Madeira, W. Toussaint, L. Vanhoutte, K. Neyt, N. Killeen, B. Malissen, 
et al. 2013. Conventional and monocyte-derived CD11b+ dendritic 
cells initiate and maintain T helper 2 cell-mediated immunity to house 
dust mite allergen. Immunity. 38:322–335. http ://dx .doi .org /10 .1016 /j 
.immuni .2012 .10 .016
Robinette, M.L., A. Fuchs, V.S. Cortez, J.S. Lee, Y. Wang, S.K. Durum, S. 
Gilfillan, M. Colonna, and C. Immunological Genome. Immunological 
Genome Consortium. 2015. Transcriptional programs define molecular 
characteristics of innate lymphoid cell classes and subsets. Nat. Immunol. 
16:306–317. http ://dx .doi .org /10 .1038 /ni .3094
Sauer, S. 2015. Ligands for the nuclear peroxisome proliferator-activated 
receptor γ. Trends Pharmacol. Sci. 36:688–704 (published erratum appears 
in Trends Pharmacol. Sci. 2016. 37:167). http ://dx .doi .org /10 .1016 /j 
.tips .2015 .06 .010
Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T.K. McClanahan, G. 
Zurawski, M. Moshrefi, J. Qin, X. Li, et al. 2005. IL-33, an interleukin-1-
like cytokine that signals via the IL-1 receptor-related protein ST2 and 
induces T helper type 2-associated cytokines. Immunity. 23:479–490. http 
://dx .doi .org /10 .1016 /j .immuni .2005 .09 .015
Schneider, C., S.P. Nobs, A.K. Heer, M. Kurrer, G. Klinke, N. van Rooijen, 
J. Vogel, and M. Kopf. 2014a. Alveolar macrophages are essential for 
protection from respiratory failure and associated morbidity following 
influenza virus infection. PLoS Pathog. 10:e1004053. http ://dx .doi .org 
/10 .1371 /journal .ppat .1004053
Schneider, C., S.P. Nobs, M. Kurrer, H. Rehrauer, C. Thiele, and M. Kopf. 
2014b. Induction of the nuclear receptor PPAR-γ by the cytokine GM-
CSF is critical for the differentiation of fetal monocytes into alveolar 
macrophages. Nat. Immunol. 15:1026–1037. http ://dx .doi .org /10 .1038 
/ni .3005
Soroosh, P., T.A. Doherty, W. Duan, A.K. Mehta, H. Choi, Y.F. Adams, Z. 
Mikulski, N. Khorram, P. Rosenthal, D.H. Broide, and M. Croft. 2013. 
Lung-resident tissue macrophages generate Foxp3+ regulatory T cells 
and promote airway tolerance. J. Exp. Med. 210:775–788. http ://dx .doi 
.org /10 .1084 /jem .20121849
Szanto, A., B.L. Balint, Z.S. Nagy, E. Barta, B. Dezso, A. Pap, L. Szeles, S. 
Poliska, M. Oros, R.M. Evans, et al. 2010. STAT6 transcription factor is 
a facilitator of the nuclear receptor PPARγ-regulated gene expression in 
macrophages and dendritic cells. Immunity. 33:699–712. http ://dx .doi 
.org /10 .1016 /j .immuni .2010 .11 .009
Szatmari, I., D. Töröcsik, M. Agostini, T. Nagy, M. Gurnell, E. Barta, K. 
Chatterjee, and L. Nagy. 2007. PPARγ regulates the function of human 
dendritic cells primarily by altering lipid metabolism. Blood. 110:3271–
3280. http ://dx .doi .org /10 .1182 /blood -2007 -06 -096222
Tan, H.T., K. Sugita, and C.A. Akdis. 2016. Novel biologicals for the treatment 
of allergic diseases and asthma. Curr. Allergy Asthma Rep. 16:70. http ://dx 
.doi .org /10 .1007 /s11882 -016 -0650 -5
Thepen, T., N. Van Rooijen, and G. Kraal. 1989. Alveolar macrophage 
elimination in vivo is associated with an increase in pulmonary immune 
response in mice. J. Exp. Med. 170:499–509. http ://dx .doi .org /10 .1084 
/jem .170 .2 .499
Townsend, M.J., P.G. Fallon, D.J. Matthews, H.E. Jolin, and A.N. McKenzie. 
2000. T1/ST2-deficient mice demonstrate the importance of T1/
ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 
191:1069–1076. http ://dx .doi .org /10 .1084 /jem .191 .6 .1069
Trifilieff, A., A. Bench, M. Hanley, D. Bayley, E. Campbell, and P. Whittaker. 
2003. PPAR-α and -γ but not -δ agonists inhibit airway inflammation in 
a murine model of asthma: In vitro evidence for an NF-κB-independent 
effect. Br. J. Pharmacol. 139:163–171. http ://dx .doi .org /10 .1038 /sj .bjp 
.0705232
van Rijt, L.S., S. Jung, A. Kleinjan, N. Vos, M. Willart, C. Duez, H.C. 
Hoogsteden, and B.N. Lambrecht. 2005. In vivo depletion of lung 
CD11c+ dendritic cells during allergen challenge abrogates the 
characteristic features of asthma. J. Exp. Med. 201:981–991. http ://dx 
.doi .org /10 .1084 /jem .20042311
3035JEM Vol. 214, No. 10
von Mutius, E. 2009. Gene-environment interactions in asthma. J. Allergy 
Clin. Immunol. 123:3–11. http ://dx .doi .org /10 .1016 /j .jaci .2008 .10 .046
Webb, D.C., Y. Cai, K.I. Matthaei, and P.S. Foster. 2007. Comparative roles 
of IL-4, IL-13, and IL-4Rα in dendritic cell maturation and CD4+ Th2 
cell function. J. Immunol. 178:219–227. http ://dx .doi .org /10 .4049 /
jimmunol .178 .1 .219
Willart, M.A., K. Deswarte, P. Pouliot, H. Braun, R. Beyaert, B.N. Lambrecht, 
and H. Hammad. 2012. Interleukin-1α controls allergic sensitization to 
inhaled house dust mite via the epithelial release of GM-CSF and IL-33. 
J. Exp. Med. 209:1505–1517. http ://dx .doi .org /10 .1084 /jem .20112691
Woerly, G., K. Honda, M. Loyens, J.P. Papin, J. Auwerx, B. Staels, M. Capron, 
and D. Dombrowicz. 2003. Peroxisome proliferator-activated receptors α 
and γ down-regulate allergic inflammation and eosinophil activation. J. 
Exp. Med. 198:411–421. http ://dx .doi .org /10 .1084 /jem .20021384
Wohlfert, E.A., J.R. Grainger, N. Bouladoux, J.E. Konkel, G. Oldenhove, C.H. 
Ribeiro, J.A. Hall, R. Yagi, S. Naik, R. Bhairavabhotla, et al. 2011. GATA3 
controls Foxp3+ regulatory T cell fate during inflammation in mice. J. 
Clin. Invest. 121:4503–4515. http ://dx .doi .org /10 .1172 /JCI57456
Wolfer, A., T. Bakker, A. Wilson, M. Nicolas, V. Ioannidis, D.R. Littman, 
P.P. Lee, C.B. Wilson, W. Held, H.R. MacDonald, and F. Radtke. 2001. 
Inactivation of Notch 1 in immature thymocytes does not perturb CD4 
or CD8T cell development. Nat. Immunol. 2:235–241. http ://dx .doi .org 
/10 .1038 /85294
Wynn, T.A. 2015. Type 2 cytokines: Mechanisms and therapeutic strategies. 
Nat. Rev. Immunol. 15:271–282. http ://dx .doi .org /10 .1038 /nri3831
Zhao, Y., Y. Huang, J. He, C. Li, W. Deng, X. Ran, and D. Wang. 2014. 
Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, 
attenuates airway inflammation by inhibiting the proliferation of effector 
T cells in a murine model of neutrophilic asthma. Immunol. Lett. 157:9–
15. http ://dx .doi .org /10 .1016 /j .imlet .2013 .11 .004
